Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis

NCT ID: NCT07093268

Last Updated: 2025-07-30

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-15
• Study Completion Date: 2027-01-15

Brief Summary

The purpose of this study is to investigate the safety and tolerability of intrathecal riluzole in adults with amyotrophic lateral sclerosis.

Detailed Description

ALS/MND is a progressive motor neurone disease. Oral riluzole is approved for the treatment of ALS/MND in Australia as well as other countries. Unfortunately, in pill form, the drug's efficacy is limited by erratic absorption from the gut, dosing is limited by liver toxicity, and patients often experience brain fog as a troubling side effect. Evidence from dogs suggests that receiving the same drug through an implanted pump that infuses it directly into the cerebrospinal fluid around the cells that support breathing, allows these cells to get 3 to 10 times as much riluzole , and guarantees that it is always there at the desired amount. In addition, this delivery approach should not contribute to increased brain fog.

Patients who have demonstrated the ability to tolerate oral riluzole will have a SynchroMed® II Infusion Pump and Ascenda ® Intrathecal Catheter implanted. Once deemed medically appropriate, 6-weeks of continuous IT riluzole will be administered. Safety and tolerability will be assessed by a safety committee for the first 3 participants enrolled. With Safety Committee approval, these participants will continue on 6-months of treatment and a further 7 participants will be enrolled for a total of 32 weeks treatment.

Conditions

Amyotrophic Lateral Sclerosis; Motor Neuron Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single Arm

Intrathecal riluzole continuous infusion up to 0.2 mg / hr.

Group Type: EXPERIMENTAL

Intrathecal Riluzole

Intervention Type: DRUG

Intrathecal infusion of riluzole for 6 weeks followed by 6 months treatment with safety committee approval.

Interventions

Intrathecal Riluzole

Intrathecal infusion of riluzole for 6 weeks followed by 6 months treatment with safety committee approval.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Men and women aged 18 years or older.
• Participants are ambulatory with or without an assistive device.
• Sporadic or familial ALS diagnosis with possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria.
• Slow vital capacity (SVC) measure ≥70% of predicted for gender, height, and age.
• Medically able to undergo implantation of the SynchroMed II Infusion Pump according to the judgment of the investigator, or the presence of a previously implanted IT pump (not to be used for concurrent IT infusion of another IT agent).
• Capable of reading and providing informed consent and following study procedures.
• Geographic accessibility to the study center and the ability to travel to the clinic for study visits by ground transportation.
• Women must not be able to become pregnant (eg, post menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and 3 months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal (patch or contraceptive ring, for example) contraception), intrauterine device in place for ≥3 months, barrier method in conjunction with spermicide, or another adequate method.
• Taking and tolerating oral riluzole 50 mg twice a day for at least 30 days prior screening and willingness to continue oral riluzole throughout duration of the study.
• Patients may take other drugs approved for treatment of ALS at the dose prescribed by their neurologist.

Exclusion Criteria

• Participants with bulbar-onset ALS
• Participants at risk of increased bleeding or uncontrolled bleeding during the SynchroMed II Infusion Pump implantation or following explant. This includes but is not limited to:

1. Anatomical factors at or near the site of implantation;

2. Underlying disorders of the coagulation cascade or platelet function (eg, hemophilia, Von Willebrand's disease, liver disease);

3. Administration of antiplatelet or anticoagulant medication within 7 days before or after pump implantation (eg, aspirin, clopidogrel bisulfate, rivaroxaban, nonsteroidal anti-inflammatory agents [NSAIDs]), or

4. Use of nutritional supplements (eg, St John's Wort) within 7 days before or after pump implantation.

• Presence of infection including but not limited to: meningitis, ventriculitis, skin infection, bacteremia, or septicemia.
• Testing positive for HIV (anti-HIV antibody), HBV (HBV surface antigen) or HCV (anti-HCV antibody; HCV RNA if anti-HCV antibody is positive) at screening.
• Inability to have the infusion pump implanted ≤ 2.5 cm below the skin surface.
• Body weight and size unable to accept the infusion pump bulk and weight.
• Spinal anomalies which would complicate the implantation and fixation of the catheter for IP delivery.
• Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) value > 2.0 times the upper normal.
• A life expectancy of less than 6 months, based on the judgment of the investigator.
• Presence of tracheostomy.
• The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair the ability of the participant to provide informed consent, per investigator judgment.
• History of active substance abuse within the prior year.
• At risk for committing suicide per investigator judgment.
• Clinically significant history of unstable or severe cardiac, oncologic, hepatic, or renal disease, or other medically significant illness.
• Pregnant women or women currently breastfeeding.
• Exposure to any investigational drug, device, or biologic within 30 days of screening.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Brain Trust Bio

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David Schultz, Dr

Role: PRINCIPAL_INVESTIGATOR

Flinders Medical Centre

Antony Winkel, Dr

Role: PRINCIPAL_INVESTIGATOR

Sunshine Coast University Hospital

Locations

Sunshine Coast University Hospital

Birtinya, Queensland, Australia

Flinders Medical Centre

Bedford Park, South Australia, Australia

Countries

Australia

Central Contacts

Chen Benkler, PhD

Role: CONTACT

chen.benkler@gmail.com

+1 857 285 8300

Tina Soulis, PhD

Role: CONTACT

tina.soulis@alithialifesciences.com

+61 429 300 705

Facility Contacts

Antony Winkel, Dr

Role: primary

antony.winkel@health.qld.gov.au

Helen Rodgers

Role: backup

helen.rodgers2@health.qld.gov.au

David Shcults, Dr

Role: primary

david.schultz@sa.gov.au

+618 8204 4187

Karalyn Ernst

Role: backup

Karalyn.Ernst@sa.gov.au

+618 8204 5172

Other Identifiers

ITR2023

Identifier Type: -

Identifier Source: org_study_id